Immunophage
Latest round
- Series B
Last raised
- Mar 2023
Total raised
- $76M
Investors
- 8
About Immunophage
,Ltd, dba Immunophage, operates as a medical company that engages in developing drugs for the treatment of malignant tumors, autoimmune diseases, metabolic diseases and neurodegenerative diseases. The core team of the company is composed of former GSK executives. The company's founder, Dr. Guohuang Fan, once managed the new drug R&D team at GSK China R&D Center., Ltd. Immunophage has subsidiaries in Australia and the United States. The company's main business is the research and development of targeted drugs. In the field of oncology, it focuses on developing new immunomodulatory anti-tumor drugs to reverse the tumor immunosuppressive microenvironment. In the field of autoimmune diseases, metabolic diseases and neurodegenerative diseases, the company focuses on pathological changes caused by innate immune inflammation to develop new drugs. The company generates revenue by developing medicines against cancer, autoimmune diseases, neurodegenerative disorders.
Who invested in Immunophage
8 investors across 3 rounds
See all investors in Immunophage
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunophage
Who invested in Immunophage?
Immunophage has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunophage raised?
Immunophage has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunophage last raise money?
Immunophage's most recent round on record is a Series B, in Mar 2023.
What does Immunophage do?
,Ltd, dba Immunophage, operates as a medical company that engages in developing drugs for the treatment of malignant tumors, autoimmune diseases, metabolic diseases and neurodegenerative diseases.
Where is Immunophage headquartered?
Immunophage is headquartered in Nanjing, China.
Which VCs invest in companies like Immunophage?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Immunophage's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immunophage? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.